tyrosine kinase


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to tyrosine kinase: Tyrosine Kinase Receptor

ty·ro·sine ki·nase

an enzyme that phosphorylates tyrosyl residues on certain proteins; many are products of viral oncogenes; a number of receptors (for example, receptors for epidermal growth factor, insulin, etc.) have this enzymatic activity; a misnomer, in that the physiologic substrate is not tyrosine but tyrosyl residues in a protein.

tyrosine kinase

n.
Any of a family of enzymes that phosphorylate tyrosine in certain proteins and play an important role in cell signaling. Mutations that affect their activity or expression can cause leukemia and other cancers.

tyrosine kinase

An enzyme intimately linked to signal transduction–ST, either as a receptor-type TK, which participates in transmembrane signaling, or as an intracellular TK, participating in ST to the nucleus; ↑ or ↓ TK activity is associated with various diseases, and alteration of TK activity at various points in its signaling pathway is of potential therapeutic interest; ↑ TK activity implicated in many CAs and other malignant and nonmalignant diseases, ASHD, psoriasis, inflammation; ↓ TK activity is linked to DM, X-linked agammaglobulinemia

tyrosine kinase

Any of a group of enzymes that influence signaling between cells, esp. as relates to cell growth and death, cellular adhesion and movement, and cellular differentiation. Abnormalities in tyrosine kinases are found in some human diseases, including chronic myeloid (myelogenous) leukemia.
See also: kinase
References in periodicals archive ?
Dasatinib: Sprycel[R], Bristol-Myers Squibb; a tyrosine kinase approved in 2006 to treat patients with CML who are resistant to or intolerant of imatinib
Approximately 90% of GIST cases are associated with mutations of KIT and PDGFRA tyrosine kinases, leading to dysregulation of cell growth.
Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
Until 2005, genetic cause of these hematological diseases was not clear.In the year 2005, a single point mutation (JAK2V617F) in the cytoplasmic tyrosine kinase JAK2 gene was proposed by several researchers in most of patients with PV, ET and PMF.4,6,10 Jak 2 gene is situated on chromosome 9p.24
BCR-ABL protein produced as a result of Philadelphia chromosome, has dys-regulated tyrosine kinase activity.
Patients whose tumors harbor certain, specific molecular alterations may be candidates for targeted tyrosine kinase inhibitor (TKI) therapy, which may improve survival and quality of life.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been dosed in a phase 1 study evaluating the safety and tolerability of U3-1402, an investigational and potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) whose disease has progressed while taking an EGFR tyrosine kinase inhibitor (TKI).
The company said this makes Tasigna the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) after achieving sustained deep molecular response of MR4.5 (BCR-ABL 1 International Scale </= 0.0032%) in its FDA-approved prescribing information.
In the article titled "Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications" [1], there was a missing affiliation for the second author.
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase (Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.

Full browser ?